ATE104153T1 - Rekombinantes pseudomonastoxin : konstruktion eines wirksamen immunotoxins mit wenigen nebenwirkungen. - Google Patents

Rekombinantes pseudomonastoxin : konstruktion eines wirksamen immunotoxins mit wenigen nebenwirkungen.

Info

Publication number
ATE104153T1
ATE104153T1 AT87113929T AT87113929T ATE104153T1 AT E104153 T1 ATE104153 T1 AT E104153T1 AT 87113929 T AT87113929 T AT 87113929T AT 87113929 T AT87113929 T AT 87113929T AT E104153 T1 ATE104153 T1 AT E104153T1
Authority
AT
Austria
Prior art keywords
pseudomonas exotoxin
present
modified
pseudomonastoxin
immunotoxin
Prior art date
Application number
AT87113929T
Other languages
English (en)
Inventor
Ira H Pastan
David J Fitzgerald
Sankar Adhya
Original Assignee
Ira H Pastan
David J Fitzgerald
Dassler Kg Adi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ira H Pastan, David J Fitzgerald, Dassler Kg Adi filed Critical Ira H Pastan
Application granted granted Critical
Publication of ATE104153T1 publication Critical patent/ATE104153T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT87113929T 1986-09-24 1987-09-23 Rekombinantes pseudomonastoxin : konstruktion eines wirksamen immunotoxins mit wenigen nebenwirkungen. ATE104153T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/911,227 US4892827A (en) 1986-09-24 1986-09-24 Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
EP87113929A EP0261671B1 (de) 1986-09-24 1987-09-23 Rekombinantes Pseudomonastoxin : Konstruktion eines wirksamen Immunotoxins mit wenigen Nebenwirkungen

Publications (1)

Publication Number Publication Date
ATE104153T1 true ATE104153T1 (de) 1994-04-15

Family

ID=25429936

Family Applications (2)

Application Number Title Priority Date Filing Date
AT93113917T ATE311442T1 (de) 1986-09-24 1987-09-23 Rekombinantes exotoxin von pseudomonas: konstruktion eines aktiven immunotoxins mit schwachen nebenwirkungen
AT87113929T ATE104153T1 (de) 1986-09-24 1987-09-23 Rekombinantes pseudomonastoxin : konstruktion eines wirksamen immunotoxins mit wenigen nebenwirkungen.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT93113917T ATE311442T1 (de) 1986-09-24 1987-09-23 Rekombinantes exotoxin von pseudomonas: konstruktion eines aktiven immunotoxins mit schwachen nebenwirkungen

Country Status (19)

Country Link
US (2) US4892827A (de)
EP (2) EP0261671B1 (de)
JP (3) JP2848489B2 (de)
KR (1) KR970001563B1 (de)
AT (2) ATE311442T1 (de)
AU (1) AU618722B2 (de)
CA (1) CA1336691C (de)
DE (2) DE3752387T2 (de)
DK (2) DK173301B1 (de)
ES (2) ES2253734T3 (de)
FI (1) FI105271B (de)
IE (1) IE66223B1 (de)
IL (2) IL105160A (de)
NO (1) NO180270C (de)
NZ (1) NZ221923A (de)
PT (1) PT85777B (de)
SG (1) SG96159A1 (de)
WO (1) WO1988002401A1 (de)
ZA (1) ZA877153B (de)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) * 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
IL90190A0 (en) * 1988-05-09 1989-12-15 Us Health Vector for secretion of proteins directly into periplasm or culture medium and method for synthesizing pure proteins utilizing the same
US5206353A (en) * 1988-07-23 1993-04-27 The United States Of America As Represented By The Department Of Health And Human Services CD-4/cytotoxic gene fusions
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5149782A (en) * 1988-08-19 1992-09-22 Tanox Biosystems, Inc. Molecular conjugates containing cell membrane-blending agents
ZA898139B (en) * 1988-11-17 1990-08-29 Hoffmann La Roche Recombinant interleukin-2 hybrid proteins
DE69025211T2 (de) * 1989-02-17 1996-09-19 Merck & Co Inc Protein-Antikrebsmittel
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
IL93723A (en) * 1989-03-22 1997-02-18 Merck & Co Inc Cystein modified truncated pseudomonas exotoxin A
US5621078A (en) * 1989-03-22 1997-04-15 Merck & Co., Inc. Modified pseudomonas exotoxin PE40
CA2053911C (en) * 1989-04-21 1999-11-02 Ira H. Pastan Recombinant antibody-toxin fusion protein
US6207798B1 (en) 1989-08-03 2001-03-27 Merck & Co., Inc. Modified PE40 toxin fusion proteins
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
CA2071946A1 (en) * 1989-12-21 1991-06-22 Ira H. Pastan Toxin for construction of immunotoxins
US5458878A (en) * 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
AU644139B2 (en) * 1990-01-02 1993-12-02 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Target-specific, cytotoxic, recombinant pseudomonas exotoxin
US5110912A (en) * 1990-03-02 1992-05-05 Seragen, Inc. Purification of il-2-containing hybrid compounds
WO1991018100A1 (en) * 1990-05-11 1991-11-28 THE UNITED SATES OF AMERICA, represented by THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE Improved pseudomonas exotoxins of low animal toxicity and high cytocidal activity
IL98528A0 (en) * 1990-06-21 1992-07-15 Merck & Co Inc Pharmaceutical compositions containing hybrid for killing bladder cancer cells
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5571894A (en) * 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
FR2672616B1 (fr) * 1991-02-08 1994-09-23 Roussel Uclaf Sequences nucleotidiques codant pour des regions variables de chaines alpha des recepteurs de lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques.
ATE338134T1 (de) * 1991-02-08 2006-09-15 Aventis Pharma Sa Nukleotidsequenzen, die für die veränderlichen bereiche der alpha-ketten menschlicher t-zell- rezeptoren kodieren sowie ihre verwendungen
KR100227303B1 (ko) * 1991-02-12 1999-12-01 장-끌로드 비에이으포스 인체 t 임파구 수용체의 베타 사슬의 가변성 영역을 코딩하는 뉴클레오티드 서열, 대응하는 펩티드 세그먼트 및 진단 및 치료 용도
US5328984A (en) * 1991-03-04 1994-07-12 The United States As Represented By The Department Of Health & Human Services Recombinant chimeric proteins deliverable across cellular membranes into cytosol of target cells
US5223604A (en) * 1991-06-25 1993-06-29 S.P.I. Synthetic Peptides Incorporated Pseudomonas exoenzyme s peptide composition and method
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
CA2081952A1 (en) * 1991-11-08 1993-05-09 John J. Donnelly Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use
CA2136724A1 (en) * 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
EP0861091B1 (de) * 1995-10-13 2003-08-20 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of Health and Human Services Immunotoxin enthaltend ein disulfid-stabilisiertes antikörperfragment
TR199801722T2 (xx) 1996-03-01 1998-12-21 Novartis Ag Peptit imm�nojenler.
US6426075B1 (en) 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US20030198772A1 (en) * 1997-06-26 2003-10-23 Weder Donald E. Polymeric materials having a texture or appearance simulating the texture or appearance of paper
US20020004113A1 (en) * 1997-06-26 2002-01-10 Weder Donald E. Decorative cover for flower pot or floral grouping formed of polymeric materials having a texture or appearance simulating the texture or appearance of paper
AU731703B2 (en) * 1997-07-11 2001-04-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pseudomonas exotoxin A-like chimeric immunogens
US7314632B1 (en) * 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
US6077676A (en) * 1997-12-18 2000-06-20 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US6794128B2 (en) 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies
AU2004201055B2 (en) * 1998-04-24 2007-08-23 The Regents Of The University Of California Internalizing ErbB2 antibodies
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
US20030143233A1 (en) * 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US20030103948A1 (en) * 1999-06-07 2003-06-05 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6838553B1 (en) * 1999-10-05 2005-01-04 Academia Sinica Peptide repeat immunogens
US7078486B2 (en) * 1999-12-10 2006-07-18 Spectral Diagnostics, Inc. Single-chain polypeptides comprising troponin I and troponin C
US20050287638A1 (en) * 2000-04-25 2005-12-29 Weigel Paul H Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
US6979555B2 (en) * 2000-04-25 2005-12-27 Board Of Regents Of The University Of Oklahoma Hyaluronan receptor for endocytosis
EP1379550B1 (de) * 2000-12-21 2009-03-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Ein chimäres protein das nichttoxische pseudomonas exotoxin a und typ iv pilin sequenzen enthält
WO2002086093A2 (en) * 2001-04-25 2002-10-31 Weigel Paul H Methods of using a hyaluronan receptor
DE60236450D1 (de) 2001-09-26 2010-07-01 Us Health Mutierte anti-cd22-antikörper mit erhöhter affinität zu cd22-exprimierenden leukämiezellen
CA2466443A1 (en) * 2001-11-09 2003-05-15 Neopharm, Inc. Selective treatment of il-13 expressing tumors
WO2004087758A2 (en) * 2003-03-26 2004-10-14 Neopharm, Inc. Il 13 receptor alpha 2 antibody and methods of use
PT2829283T (pt) 2003-04-30 2017-09-08 Univ Zuerich Método para tratamento do cancro utilizando uma imunotoxina
DE602004027291D1 (de) * 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
US7999077B2 (en) * 2004-09-30 2011-08-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IRTA2 antibodies and methods of use
CA2583226A1 (en) 2004-10-04 2006-04-20 Trinity Biosystems, Inc. Methods and compositions for immunizing against pseudomonas infection
AU2005296064A1 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
CA2591992A1 (en) 2004-12-22 2006-06-29 The Salk Institute For Biological Studies Compositions and methods for producing recombinant proteins
WO2006125076A2 (en) 2005-05-18 2006-11-23 Trinity Biosystems, Inc. Methods and compositions for immunizing against chlamydia infection
ATE524489T1 (de) * 2005-07-29 2011-09-15 Us Gov Health & Human Serv Mutierte pseudomonas-exotoxine mit reduzierter antigenität
US20090148401A1 (en) * 2005-12-05 2009-06-11 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
US7666991B2 (en) * 2005-12-05 2010-02-23 Trinity Biosystems, Inc. Compositions for needleless delivery of antibodies
WO2007109110A2 (en) 2006-03-16 2007-09-27 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
EP1878744A1 (de) * 2006-07-13 2008-01-16 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Epitope-Tag für an der Oberfläche exprimierte T-Zell Rezeptor Proteine, deren Anwendung und Verfahren zur Selection von Wirtszellen, die sie exprimieren
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
EP2178559B1 (de) 2007-07-20 2015-06-24 The General Hospital Corporation Rekombinante vibrio-cholerae-exotoxine
ES2525488T3 (es) 2007-09-04 2014-12-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Deleciones en el dominio II de la exotoxina A de pseudomonas que reducen la toxicidad inespecífica
MX2010003099A (es) * 2007-09-21 2010-05-17 Univ California Interferon de objetivo demuestra actividades potentes apoptoticas y antitumorales.
JP5836125B2 (ja) 2008-10-16 2015-12-24 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
WO2011031441A1 (en) 2009-08-28 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Therapy with a chimeric molecule and a pro-apoptotic agent
US8936792B2 (en) 2009-09-11 2015-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pseudomonas exotoxin a with reduced immunogenicity
WO2011100455A1 (en) 2010-02-12 2011-08-18 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inhibition of antibody responses to foreign proteins
US8530171B2 (en) 2010-03-30 2013-09-10 Pfenex Inc. High level expression of recombinant toxin proteins
EP2582727B8 (de) 2010-06-16 2017-04-19 University of Pittsburgh- Of the Commonwealth System of Higher Education Antikörper zu endoplasmin und deren verwendung
DK3434346T3 (da) 2010-07-30 2020-12-07 Medimmune Llc Oprensede aktive polypeptider eller immunokonjugater
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AR084020A1 (es) * 2010-11-30 2013-04-17 Genentech Inc Anticuerpos para el receptor de la barrera hematoencefalica de baja afinidad y sus usos
US9206257B2 (en) 2011-04-19 2015-12-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
CN103748107B (zh) 2011-06-09 2020-06-02 美利坚合众国, 由健康及人类服务部部长代表 具有免疫原性较小的t细胞和/或b细胞表位的假单胞菌外毒素a
US8932586B2 (en) 2011-09-06 2015-01-13 Intrexon Corporation Modified forms of Pseudomonas exotoxin A
WO2013039916A1 (en) 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
EP3301110A1 (de) 2011-09-16 2018-04-04 The USA, as represented by The Secretary, Department of Health and Human Services Pseudomonas exotoxin a mit weniger immunogenen b-zellepitopen
ES2654160T3 (es) 2011-10-04 2018-02-12 Igem Therapeutics Limited Anticuerpos de IgE anti-HMW-MAA
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
WO2013181543A1 (en) 2012-06-01 2013-12-05 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
CA2882753C (en) 2012-08-21 2021-08-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mesothelin domain-specific monoclonal antibodies and use thereof
JP6307085B2 (ja) 2012-09-27 2018-04-04 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズＴｈｅ Ｕｎｉｔｅｄ Ｓｔａｔｅｓ ｏｆ Ａｍｅｒｉｃａ，ａｓ ｒｅｐｒｅｓｅｎｔｅｄ ｂｙ ｔｈｅ Ｓｅｃｒｅｔａｒｙ，Ｄｅｐａｒｔｍｅｎｔ ｏｆ Ｈｅａｌｔｈ ａｎｄ Ｈｕｍａｎ Ｓｅｒｖｉｃｅｓ メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
WO2014089354A1 (en) 2012-12-07 2014-06-12 The Regents Of The University Of California Cd138-targeted interferon demonstrates potent apoptotic and anti-tumor activities
US9764006B2 (en) 2012-12-10 2017-09-19 The General Hospital Corporation Bivalent IL-2 fusion toxins
DK2934597T3 (en) 2012-12-20 2019-02-11 Medimmune Llc PROCEDURES FOR PREPARING IMMUNCONJUGATES
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
JP6584012B2 (ja) 2013-10-06 2019-10-02 アメリカ合衆国 改変シュードモナス外毒素ａ
EP3054987B1 (de) 2013-10-11 2019-10-09 The United States of America, represented by the Secretary, Department of Health and Human Services Tem-8-antikörper und deren verwendung
EP3066118B1 (de) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
US10246505B2 (en) 2013-11-25 2019-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors to control HIV infection
EP3102245B1 (de) 2014-02-05 2021-09-08 Molecular Templates, Inc. Verfahren zum abtasten, auswählen und identifizieren von cytotoxischen rekombinanten polypeptiden auf grundlage einer vorläufigen minderung der ribotoxizität
BR112016025866A2 (pt) 2014-05-07 2017-12-12 Applied Molecular Transp Llc composição farmacêutica, método para tratar uma doença anti-inflamatória em um indivíduo, método para tratar uma doença autoimune em um indivíduo, método para tratar um câncer em um indivíduo, uso de uma molécula de fusão que não ocorre naturalmente, método para tratar um distúrbio metabólico em um indivíduo, método para tratar uma doença hepática gordurosa em um indivíduo, método para tratar um distúrbio de deficiência de hormônio de crescimentoem um indivíduo, e, polinucleotídeo que codifica uma molécula de fusão
EP3473271B1 (de) 2014-07-31 2022-07-20 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Humane monoklonale antikörper gegen epha4 und deren verwendung
CA2961609C (en) 2014-09-17 2023-03-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 antibodies (b7h3)
WO2016146833A1 (en) 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
CA2981509A1 (en) 2015-03-30 2016-10-06 The Board Of Regents Of The Nevada System Of Higher Educ. On Behalf Of The University Of Nevada, La Compositions comprising talens and methods of treating hiv
CN108139375A (zh) 2015-06-26 2018-06-08 贝斯以色列女执事医疗中心股份有限公司 靶向髓样衍生的抑制细胞中的四跨膜蛋白33(tspan33)的癌症疗法
EP3350224B1 (de) 2015-09-20 2024-06-19 The United States of America, as Represented By the Secretary, Department of Health and Human Services Für fibroblastenwachstumsfaktor-rezeptor 4 (fgfr4) spezifische monoklonale antikörper und verfahren zu deren verwendung
WO2017064190A1 (en) 2015-10-13 2017-04-20 Sanofi Pasteur Immunogenic compositions against s. aureus
EP3184547A1 (de) 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg-antikörper und verfahren zur verwendung
JP6901493B2 (ja) 2015-11-13 2021-07-14 アメリカ合衆国 抗ｂｃｍａポリペプチド及びタンパク質
WO2017196847A1 (en) 2016-05-10 2017-11-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Variable new antigen receptor (vnar) antibodies and antibody conjugates targeting tumor and viral antigens
WO2017214182A1 (en) 2016-06-07 2017-12-14 The United States Of America. As Represented By The Secretary, Department Of Health & Human Services Fully human antibody targeting pdi for cancer immunotherapy
CA3031559A1 (en) 2016-08-02 2018-02-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (gpc2) and use thereof
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
US11236171B2 (en) 2016-12-21 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies specific for FLT3 and uses thereof
US11390683B2 (en) 2017-05-18 2022-07-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides and proteins
EP3625256A1 (de) 2017-05-19 2020-03-25 The U.S.A. as represented by the Secretary, Department of Health and Human Services Humaner monoklonaler antikörper gegen tnfr2 zur krebsimmuntherapie
WO2019005208A1 (en) 2017-06-30 2019-01-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services ANTIBODIES TO HUMAN MESOTHELIN AND USES IN ANTICANCER THERAPY
CA3066953A1 (en) 2017-06-30 2019-01-03 Lentigen Technology, Inc. Human monoclonal antibodies specific for cd33 and methods of their use
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
US11795235B2 (en) 2017-09-18 2023-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotoxins with albumin binding domain
EP3691693A4 (de) 2017-10-06 2021-08-25 University Of Utah Research Foundation Fusionsprotein zur gezielten therapie einer autoimmunerkrankung
KR20210076881A (ko) 2018-03-08 2021-06-24 어플라이드 몰레큘라 트랜스포트 인크. 경구 전달용 독소-유래 전달 구조체
WO2020014482A1 (en) 2018-07-12 2020-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Affinity matured cd22-specific monoclonal antibody and uses thereof
US12012463B2 (en) 2018-08-08 2024-06-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-2 and uses thereof
KR102353086B1 (ko) * 2018-09-07 2022-01-20 아주대학교산학협력단 신규 면역독소 제조방법
TW202031678A (zh) 2018-11-07 2020-09-01 美商應用分子運輸公司 用於胞移作用及相關方法之遞送構築體
CN113347997A (zh) 2018-11-07 2021-09-03 应用分子运输公司 用于经口递送异源有效载荷的Cholix衍生的携带体
EP3883608A1 (de) 2019-01-08 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services Speziesübergreifende einzeldomänenantikörper gegen mesothelin zur behandlung von soliden tumoren
US12122843B2 (en) 2019-01-22 2024-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
EP3927731A4 (de) 2019-02-19 2022-12-28 The Regents of the University of Colorado, a body corporate Bispezifische immunotoxine zur targeting von menschlichen cd25s-ccr4+ tumoren und regulatorischen t-zellen
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP4031250A1 (de) 2019-10-22 2022-07-27 The United States of America, as represented by the Secretary, Department of Health and Human Services Gegen b7h3 (cd276) gerichtete hochaffine nanokörper zur behandlung von multiplen soliden tumoren
WO2021097289A1 (en) 2019-11-15 2021-05-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pegylated recombinant immunotoxins
EP4110823A1 (de) 2020-02-26 2023-01-04 A2 Biotherapeutics, Inc. Gegen mage-a3-peptid-mhc-komplexe gerichtete polypeptide und verfahren zu deren verwendung
US20230391852A1 (en) 2020-10-26 2023-12-07 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
MX2023007178A (es) 2020-12-22 2023-06-30 Jiangsu Hengrui Pharmaceuticals Co Ltd Complejo de anticuerpo anti-il-4r o fragmento de enlace a antigeno y uso medico del mismo.
WO2022232612A1 (en) 2021-04-29 2022-11-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
US20240270851A1 (en) 2021-06-09 2024-08-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
US20240417446A1 (en) 2021-10-26 2024-12-19 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
CA3240254A1 (en) 2021-12-17 2023-06-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin polypeptides, proteins, and chimeric antigen receptors
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024104584A1 (en) 2022-11-17 2024-05-23 University Of Cape Town Deimmunized pseudomonas exotoxin a
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody
AU2024295016A1 (en) 2023-07-20 2026-02-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025106427A1 (en) 2023-11-14 2025-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing and protective monoclonal antibodies against respiratory syncytial virus (rsv)
WO2025171238A1 (en) 2024-02-07 2025-08-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind the juxta-membrane region of mesothelin and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470924A (en) * 1981-12-30 1984-09-11 Iglewski Barbara M Nontoxic, immunologically crossreactive toxin A protein from Pseudomonas aeruginosa
DE3369466D1 (en) * 1982-05-12 1987-03-05 Harvard College Fused genes encoding hybrid proteins, cloning vectors containing them and the use thereof
US4545985A (en) * 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
US4894443A (en) * 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
ES8708014A1 (es) * 1984-06-07 1987-09-01 Murphy John R Un procedimiento para preparar un gen fusionado que codifica una proteina hibrida susceptible de marcado y empleo en diagnosis.
US4892827A (en) * 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4867962A (en) * 1988-02-26 1989-09-19 Neorx Corporation Functionally specific antibodies

Also Published As

Publication number Publication date
JPH02502063A (ja) 1990-07-12
DE3789587T2 (de) 1994-07-28
FI891321A0 (fi) 1989-03-21
DE3789587D1 (de) 1994-05-19
ES2253734T3 (es) 2006-06-01
WO1988002401A1 (en) 1988-04-07
EP0583794A1 (de) 1994-02-23
NO180270C (no) 1997-03-19
KR970001563B1 (ko) 1997-02-11
JP2848489B2 (ja) 1999-01-20
ES2074042T3 (es) 1995-09-01
PT85777B (pt) 1990-07-31
JP3053087B2 (ja) 2000-06-19
IL83971A (en) 1994-06-24
EP0583794B1 (de) 2005-11-30
DE3752387T2 (de) 2006-06-08
DE3752387D1 (de) 2006-01-05
NO180270B (no) 1996-12-09
DK173301B1 (da) 2000-06-19
FI891321L (fi) 1989-03-21
IL105160A (en) 1997-07-13
EP0261671A3 (en) 1988-08-10
IE950321L (en) 1988-03-24
AU8021187A (en) 1988-04-21
JPH10136988A (ja) 1998-05-26
EP0261671A2 (de) 1988-03-30
ZA877153B (en) 1989-08-30
JP2960697B2 (ja) 1999-10-12
DK173560B1 (da) 2001-03-12
DK276488A (da) 1988-05-20
EP0261671B1 (de) 1994-04-13
JPH11253181A (ja) 1999-09-21
IL83971A0 (en) 1988-02-29
PT85777A (en) 1987-10-01
IE66223B1 (en) 1995-12-13
AU618722B2 (en) 1992-01-09
CA1336691C (en) 1995-08-15
DK276488D0 (da) 1988-05-20
FI105271B (fi) 2000-07-14
DK199901377A (da) 1999-09-28
NO882269L (no) 1988-05-24
NZ221923A (en) 1991-12-23
NO882269D0 (no) 1988-05-24
IE872553L (en) 1988-03-24
ATE311442T1 (de) 2005-12-15
KR890700162A (ko) 1989-03-10
US5696237A (en) 1997-12-09
US4892827A (en) 1990-01-09
SG96159A1 (en) 2003-05-23

Similar Documents

Publication Publication Date Title
ATE104153T1 (de) Rekombinantes pseudomonastoxin : konstruktion eines wirksamen immunotoxins mit wenigen nebenwirkungen.
EP4406608A3 (de) Protein-wirkstoff-konjugate mit camptothecin-analoga und verfahren zur verwendung davon
ES550152A0 (es) Conjugados estables de polisacarido-proteina
NO901986L (no) Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler.
DK1254237T3 (da) Aggregatfri uratoxidase til fremstilling af ikke-immunogene polymerkonjugater
DE69807679D1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
OA09760A (fr) "Conjugués de protéine et de polyéthylène glycol".
NZ334828A (en) Contains no O-acetyl groups detectable by NMR and binds to antibodies to S.aureus further conjugated with Pseudomonas aeruginosa exotoxin A as an immunocarrier to detect S.aureus infection
DE69838979D1 (de) Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren
NO885199D0 (no) FremgangsmŸte for fremstilling av monoklonale antistoffkonjugater.
MY102878A (en) Starburst conjugates
TR199701547T1 (xx) Polisakarit antijen protein e�leni�i i�eren a��.
DE69910216D1 (de) Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung
WO1999004820A3 (en) Cytolysis of target cells by superantigen conjugates inducing t-cell activation
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
IL97776A (en) Composition comprising a conjugate of a ZME antibody and a biological response modifier
ATE126523T1 (de) Saccharid-modifizierte, wasserlösliche proteine.
ATE527358T1 (de) Ribosomen inaktivierendes protein vom typ-1
ES8203613A1 (es) Un procedimiento para la preparacion de una composicion inductora de interferon.
TR199701335T1 (xx) Diatomlu toprak ha�erat bile�imi
SE8504371L (sv) Alkoholiska drycker med hog proteinhalt och forfarande for framstellning derav

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time